🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Jeanny B. Aragon‐Ching

Inova Fairfax Hospital

ORCID: 0000-0002-6714-141X

Also affiliated with Virginia Cancer Institute

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors”.

Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors

Journal for ImmunoTherapy of Cancer(2022)10.1136/jitc-2022-005147
N/A
1.7DataRank · unranked
66 citations

Michael J. Pishvaian, Margaret K. Callahan, Amy Weise, Branimir I. Šikić, Osama E. Rahma +19 more

The Potential Role for Immunotherapy in Biochemically Recurrent Prostate Cancer

Urologic Clinics of North America(2020)10.1016/j.ucl.2020.07.004
N/A
0.373DataRank · unranked
11 citations

David J. Einstein, Fatima Karzai, William L. Dahut, James L. Gulley, Jeanny B. Aragon‐Ching +2 more

Emerging treatment options for prostate cancer

Expert Review of Anticancer Therapy(2023)10.1080/14737140.2023.2208352
N/A
0DataRank · unranked
19 citations

Elias Chandran, Fatima Karzai, Ravi A. Madan, Jeanny B. Aragon‐Ching, Mohammad Atiq

Biochemically recurrent prostate cancer in the era of EMBARK and PSMA PET imaging: everything has changed, except the patients

Current Opinion in Oncology(2024)10.1097/cco.0000000000001030
N/A
0DataRank · unranked
10 citations

Jeanny B. Aragon‐Ching, Fatima Karzai, Ravi A. Madan, David J. Einstein

Radium 223 without androgen deprivation therapy (ADT) in patients (Pts) with biochemically recurrent prostate cancer (BCR) and PET findings in the bones.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.5_suppl.180
N/A
0DataRank · unranked
0 citations

Fatima Karzai, Philip M. Arlen, Clara Chen, Esther Mena, Liza Lindenberg +11 more